Endologix Stung By Double-Whammy Suspensions

The specialist in stent grafts for abdominal aortic aneurysms, Endologix, has suspended shipments of its AFX AAA repair system after discovering that a manufacturing issue was causing damage to some devices. This is the second knock-back the company's biggest seller has had in as many weeks, following a CE-mark suspension earlier this month.

Endologix Inc., said to be the biggest company dedicated to endovascular treatment of abdominal aortic aneurysms (AAAs), saw its share price plummet to a 52-week low after it announced it was temporarily holding off shipments of its AFX AAA repair system while it resolves a manufacturing issue that was causing damage to the graft material in some sizes of the device. Sales of AFX account for around 60%-65% of Endologix's total revenue.

The firm's stock price fell to $5.26 amidst heavy volume trading on the Nasdaq on Dec. 27. This represents a 27% drop from $7.19, the closing price on Dec. 23,...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiology

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Digital Health And AI Tools Advance Cardiac Event Prediction, SCAI 2025 Data Show

 
• By 

Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.

Thousands Of Cardiac Digital Twins Reveal Novel Connections With Mental Health

 

King’s College London, Imperial College London and The Alan Turing Institute constructed cardiac digital twins at scale, creating over 3,400, in a new study using UK Biobank data published in Nature Cardiovascular Research on 16 May.

Abbott’s FreeStyle Libre CGM Reduces Cardiovascular Disease-Related Hospitalization

 

The REFLECT studies showed a 78% reduction in cardiovascular disease-related hospitalization for people living with type 1 diabetes with prior low blood sugar episodes.

More from Device Area

Bone Surgery Startup Surgify Medical Raises $7.9m

 

Surgify Medical’s selective drill tip, Surgify Halo, is “an obvious choice for surgeons,” said Boris Hofmann, head of ZEISS Ventures and lead investor in the company’s series A funding round.

German Bionic Launches ‘Strongest Exoskeleton To Date’

 

German Bionic’s new exoskeleton Exia helps healthcare practitioners, nurses, and other caregivers to lift and move patients by supporting muscle movement and reducing the risk of injury.

Medtronic To Spin Out Diabetes Unit As New Products Solidify Turn-Around Story

 
• By 

Medtronic’s diabetes spin-out – a process likely to run up to 18 months and involve 20% IPO followed by a split-off for Medtronic shareholders – will allow firm to focus on higher-margin devices.